口服地屈孕酮与阴道微粒化孕酮凝胶用于体外受精黄体期支持的比较:一项随机临床试验
Lotus II 是一项在10个国家37个中心开展的随机、开放标签、III期非劣效性研究,纳入1034例行体外受精的绝经前女性,比较口服地屈孕酮30 mg每日与8%微粒化阴道孕酮凝胶90 mg每日用于黄体期支持。结果显示,口服地屈孕酮在妊娠12周胎心存在方面非劣效于凝胶(非劣效界值10%),12周妊娠率分别为38.7%与35.0%(校正差值3.7%,95%CI -2.3至9.7),活产率分别为34.4%与32.5%(校正差值1.9%,95%CI -4.0至7.8),安全性与凝胶相似。
要点
- 口服地屈孕酮30 mg每日在12周胎心存在方面非劣效于8%微粒化阴道孕酮凝胶90 mg每日(非劣效界值10%)。
- 全分析集12周妊娠率:口服地屈孕酮组38.7%(191/494) vs 凝胶组35.0%(171/489),校正差值3.7%(95%CI -2.3至9.7)。
- 全分析集活产率:口服地屈孕酮组34.4%(170/494) vs 凝胶组32.5%(159/489),校正差值1.9%(95%CI -4.0至7.8)。
核心结论
- 口服地屈孕酮在妊娠12周胎心存在方面非劣效于8%微粒化阴道孕酮凝胶(非劣效界值10%)。
- 口服地屈孕酮耐受性良好,安全性与微粒化阴道孕酮凝胶相似。
- 作者认为,由于疗效和耐受性相当且口服给药方便,地屈孕酮可能替代微粒化阴道孕酮凝胶作为新鲜周期体外受精黄体期支持的标准治疗。
研究设计与样本
- Lotus II为随机、开放标签、多中心、III期非劣效性研究,于2015年8月至2017年5月在10个国家37个体外受精中心开展。
- 共纳入1034名绝经前女性(>18至<42岁)行体外受精,按1:1随机(按国家和年龄组分层)接受口服地屈孕酮30 mg每日或8%微粒化阴道孕酮凝胶90 mg每日。
- 口服地屈孕酮组n=520,微粒化阴道孕酮凝胶组n=514,自取卵日起用药,黄体期支持持续至妊娠12周。
- 主要结局为经阴道超声确定的妊娠12周胎心存在。
主要发现
- 全分析集12周妊娠率:口服地屈孕酮组38.7%(191/494) vs 微粒化阴道孕酮凝胶组35.0%(171/489),校正差值3.7%(95%CI -2.3至9.7)。
- 全分析集活产率:口服地屈孕酮组34.4%(170/494) vs 微粒化阴道孕酮凝胶组32.5%(159/489),校正差值1.9%(95%CI -4.0至7.8)。
- 口服地屈孕酮耐受性良好,安全性与微粒化阴道孕酮凝胶相似。
关键数值与推荐
- 非劣效界值为10%。
- 主要结局非劣效性成立:12周妊娠率口服地屈孕酮组38.7%(191/494) vs 微粒化阴道孕酮凝胶组35.0%(171/489),校正差值3.7%(95%CI -2.3至9.7)。
临床怎么用
- 作者认为,口服地屈孕酮是微粒化阴道孕酮凝胶的可行替代选择,因两者疗效和耐受性相当。
- 作者认为,由于口服给药方便,地屈孕酮可能替代微粒化阴道孕酮凝胶作为新鲜周期体外受精黄体期支持的标准治疗。
- 作者指出,本研究探讨的是新鲜周期体外受精中口服地屈孕酮的使用,其在无黄体的程序化冻融周期中的疗效需进一步研究。
局限性
- 该研究把握度基于持续妊娠率计算,但临床更关注的主要目标可能是活产率。
- 本研究为开放标签设计,因技术原因无法为微粒化阴道孕酮凝胶制作安慰剂施药器,可能增加主观终点报告的偏倚风险。
- 本研究探讨的是新鲜周期体外受精中口服地屈孕酮的使用,其在无黄体的程序化冻融周期中的疗效需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is oral dydrogesterone 30 mg daily non-inferior to 8% micronized vaginal progesterone (MVP) gel 90 mg daily for luteal phase support in IVF? SUMMARY ANSWER: Oral dydrogesterone demonstrated non-inferiority to MVP gel for the presence of fetal heartbeats at 12 weeks of gestation (non-inferiority margin 10%). WHAT IS KNOWN ALREADY: The standard of care for luteal phase support in IVF is the use of MVP; however, it is associated with vaginal irritation, discharge and poor patient compliance. Oral dydrogesterone may replace MVP as the standard of care if it is found to be efficacious with an acceptable safety profile. STUDY DESIGN, SIZE, DURATION: Lotus II was a randomized, open-label, multicenter, Phase III, non-inferiority study conducted at 37 IVF centers in 10 countries worldwide, from August 2015 until May 2017. In total, 1034 premenopausal women (>18 to <42 years of age) undergoing IVF were randomized 1:1 (stratified by country and age group), using an Interactive Web Response System, to receive oral dydrogesterone 30 mg or 8% MVP gel 90 mg daily. PARTICIPANTS/MATERIALS, SETTING, METHODS: Subjects received either oral dydrogesterone (n = 520) or MVP gel (n = 514) on the day of oocyte retrieval, and luteal phase support continued until 12 weeks of gestation. The primary outcome measure was the presence of fetal heartbeats at 12 weeks of gestation, as determined by transvaginal ultrasound. MAIN RESULTS AND THE ROLE OF CHANCE: Non-inferiority of oral dydrogesterone was demonstrated, with pregnancy rates in the full analysis sample (FAS) at 12 weeks of gestation of 38.7% (191/494) and 35.0% (171/489) in the oral dydrogesterone and MVP gel groups, respectively (adjusted difference, 3.7%; 95% CI: -2.3 to 9.7). Live birth rates in the FAS of 34.4% (170/494) and 32.5% (159/489) were obtained for the oral dydrogesterone and MVP gel groups, respectively (adjusted difference 1.9%; 95% CI: -4.0 to 7.8). Oral dydrogesterone was well tolerated and had a similar safety profile to MVP gel. LIMITATIONS, REASONS FOR CAUTION: The analysis of the results was powered to consider the ongoing pregnancy rate, but a primary objective of greater clinical interest may have been the live birth rate. This study was open-label as it was not technically feasible to make a placebo applicator for MVP gel, which may have increased the risk of bias for the subjective endpoints reported in this study. While the use of oral dydrogesterone in fresh-cycle IVF was investigated in this study, further research is needed to investigate its efficacy in programmed frozen-thawed cycles where corpora lutea do not exist. WIDER IMPLICATIONS OF THE FINDINGS: This study demonstrates that oral dydrogesterone is a viable alternative to MVP gel, due to its comparable efficacy and tolerability profiles. Owing to its patient-friendly oral administration route, dydrogesterone may replace MVP as the standard of care for luteal phase support in fresh-cycle IVF. STUDY FUNDING/COMPETING INTERESTS(S): This study was sponsored and supported by Abbott. G.G. has received investigator fees from Abbott during the conduct of the study. Outside of this submitted work, G.G. has received non-financial support from MSD, Ferring, Merck-Serono, IBSA, Finox, TEVA, Glycotope and Gedeon Richter, as well as personal fees from MSD, Ferring, Merck-Serono, IBSA, Finox, TEVA, Glycotope, VitroLife, NMC Healthcare, ReprodWissen, Biosilu, Gedeon Richter and ZIVA. C.B. is the President of the Belgian Society of Reproductive Medicine (unpaid) and Section Editor of Reproductive BioMedicine Online. C.B. has received grants from Ferring Pharmaceuticals, participated in an MSD sponsored trial, and has received payment from Ferring, MSD, Biomérieux, Abbott and Merck for lectures. G.S. has no conflicts of interest to be declared. A.P. is the General Secretary of the Indian Society of Assisted Reproduction (2017-2018). B.D. is President of Pune Obstetric and Gynecological Society (2017-2018). D.-Z.Y. has no conflicts of interest to be declared. Z.-J.C. has no conflicts of interest to be declared. E.K. is an employee of Abbott Laboratories GmbH, Hannover, Germany and owns shares in Abbott. C.P.-F. is an employee of Abbott GmbH & Co. KG, Wiesbaden, Germany and owns shares in Abbott. H.T.'s institution has received grants from Merck, MSD, Goodlife, Cook, Roche, Origio, Besins, Ferring and Mithra (now Allergan); and H.T. has received consultancy fees from Finox-Gedeon Richter, Merck, Ferring, Abbott and ObsEva. TRIAL REGISTRATION NUMBER: NCT02491437 (clinicaltrials.gov). TRIAL REGISTRATION DATE: 08 July 2015. DATE OF FIRST PATIENT’S ENROLLMENT: 17 August 2015.
引用
- Griesinger G, Blockeel C, Sukhikh GT, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018. PMID: 30304457. doi:10.1093/humrep/dey306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。